{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002944","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.580218+00:00","generated_at":"2026-05-22T06:17:17.199873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aptose Q1 net loss $5.5M, cash only until end-May 2025; cites need for financing","bullets":["Net loss of $5.5M for Q1 2025 vs. $9.6M a year ago; EPS loss $2.61.","Cash and restricted cash $4.7M; company expects runway only through May 2025.","TUSCANY trial: all six patients on 40 or 80 mg TUS+VEN+AZA achieved complete remissions.","Common shares delisted from Nasdaq effective April 2, 2025 due to equity deficiency.","Management pursuing financing and cost cuts to extend cash runway beyond May 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002944","json":"https://secwatch.observer/filing/0001171843-25-002944.json","markdown":"https://secwatch.observer/filing/0001171843-25-002944.md","text":"https://secwatch.observer/filing/0001171843-25-002944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325002944/0001171843-25-002944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325002944/f8k_050825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:17:17.199873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}